Public health policy decisions on medical innovations: What role can early economic evaluation play?

Health Policy

Volumn 89, Issue 2, 2009, Pages 184-192

  Hartz, Susanne ^a   John, Jürgen ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Early data; Economic evaluation; Innovation; Public health policy decision making

Indexed keywords

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; HEALTH POLICY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PUBLIC HEALTH;

EID: 58349085963     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.05.011     Document Type: Article

References (43)

1. Leidl R. Innovation - a health economic perspective. European Journal of Clinical Pharmacology 61 (2005) 693 [abstract only]
2. Langley P. In all probability. Script Magazine (2003) 22-24
3. Taylor R.S., Drummond M.F., Salkeld G., and Sullivan S.D. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. British Medical Journal 329 7472 (2000) 972-975
4. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddart G.L. Methods for the economic evaluation of health care programmes. 3 ed. (2005), Oxford University Press, Oxford
5. Hartz S, John J. The contribution of economic evaluation to decision-making in early phases of product development: a methodological and empirical review; International Journal of Technology Assessment in Health Care, accepted for publication.
6. Avorn J. The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation. Pharmacoeconomics 22 Suppl. 2 (2004) 81-86
7. Hill S., and Freemantle N. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?. Pharmacoeconomics 21 11 (2003) 761-767
8. Keech M. Using health outcomes data to inform decision-making. A pharmaceutical industry perspective. Pharmacoeconomics 19 Suppl 2 (2001) 27-31
9. Hutton J., Trueman P., and Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. International Journal of Technology Assessment in Health Care 23 4 (2007) 425-435
10. Pearson S., Miller F., and Emanuel E. Medicare's requirement for research participation as a condition of coverage: is it ethical?. Journal of the American Medical Association 296 8 (2006) 988-991
11. Tunis S., and Pearson S. Coverage options for promising technologies: Medicare's "coverage with evidence development". Health Affairs 25 5 (2006) 1218-1230
12. Douw K., Vondeling H., Eskildsen D., and Simpson S. Use of the internet in scanning the horizon for new and emerging health technologies: a survey of agencies involved in horizon scanning. Journal of Medical Internet Research 5 1 (2003) e6
13. McDaid D., and Cookson R. Evaluating health care interventions in the European Union. Health Policy 63 (2003) 133-139
14. Wild C. Horizon-scanning. ÖKZ 48 4 (2007) 16
15. Douw K., and Vondeling H. Selection of new health technologies for assessment aimed at informing decision making: a survey among horizon scanning systems. International Journal of Technology Assessment in Health Care 22 2 (2006) 177-183
16. Packer C., Simpson S., and Stevens A. International diffusion of new health technologies: a ten-country analysis of six health technologies. International Journal of Technology Assessment in Health Care 22 4 (2006) 419-428
17. Banta D. The development of health technology assessment. Health Policy 63 (2003) 121-132
18. Greiner W. Die Rolle der Pharmaökonomie zur Ressourcenallokation im Gesundheitswesen - Überblick und Implikationen für Deutschland. Gesundheitsökonomie und Qualitätsmanagement 12 (2007) 51-56
19. Schubert F. Health technology assessment. The pharmaceutical industry perspective. International Journal of Technology Assessment in Health Care 18 2 (2002) 184-191
20. Oliver A., Mossialos E., and Robinson R. Health technology assessment and its influence on health-care priority setting. International Journal of Technology Assessment in Health Care 20 1 (2004) 1-10
21. Pritchard C. The social and economic impact of emerging health technologies: mechanisms for diffusion/uptake of technologies and evidence-based planning. Organisation for Economic Co-operation and Development. Directorate for Science, Technology and Industry. DSTI(2002)1/ANN1; 2002.
22. Maynard A., and McDaid D. Evaluating health interventions: exploiting the potential. Health Policy 63 (2003) 215-226
23. Meakins J.L. Innovation in surgery: the rules of evidence. The American Journal of Surgery 183 (2002) 399-405
24. OECD. Health technologies and decision making. The OECD health project (2005), OECD Publications, Paris
25. Greenberg P.E., Arcelus A., Birnbaum H.G., Cremieux P.Y., LeLorier J., Ouellette P., et al. Pharmacoeconomics and health policy. Pharmacoeconomics 16 5 Pt 1 (1999) 425-432
26. Oh E.-H., Imanaka Y., and Evand E. Determinants of the diffusion of computed tomography and magnetic resonance imaging. International Journal of Technology Assessment in Health Care 21 1 (2005) 73-80
27. Banta D., and Vondeling H. Strategies for successful evaluation and policy-making toward health care technology on the move: the case of medical lasers. Social Science & Medicine 38 12 (1994) 1663-1674
28. Biondi G. Too early or too late: a never-ending dilemma with new technologies. Scandinavian Journal of Infectious Diseases 35 Suppl 106 (2003) 99-104
29. Mowatt G., Bower D.J., Brebner J.A., Cairns J.A., Grant A.M., and McKee L. When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies. Health Technology Assessment 1 14 (1997) i-vi, 1-149
30. Carino T., Sheingold S., and Tunis S. Using clinical trials as a condition of coverage: lessons from the National Emphysema Treatment Trial. Clinical Trials 1 1 (2004) 104-108
31. Centers for Medicare & Medicaid Services. National coverage determinations with data collection as a condition of coverage: coverage with evidence development; 2006 [cited 06.06.2007]. Available from: http://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8.
32. Goeree R., and Levin L. Building bridges between academic research and policy formulation. The PRUFE framework-an integral part of Ontario's evidence-based HTPA process. Pharmacoeconomics 24 11 (2006) 1143-1156
33. Chalkidou K., Hoy A., and Littlejohns P. Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. Journal of the Royal Society of Medicine 100 10 (2007) 453-460
34. Berndt E.R., Glennerster R., Kremer M.R., Lee J., Levine R., Weizsäcker G., et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Economics 16 (2007) 491-511
35. Webber D., and Kremer M.R. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bulletin of the World Health Organization 79 8 (2001) 735-741
36. Drummond M.F., Wilson D.A., Kanavos P., Ubel P., and Rovira J. Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care 23 1 (2007) 36-42
37. Shtern F. Government policies and high-technology imaging. Technology assessment: a perspective from the National Cancer Institute. Academic Radiology 3 (1996) S84-S87
38. Capgemini Deutschland GmbH. Regenerationstechnologien für Medizin und Biologie - Beiträge für ein strategisches Förderkonzept (Abschlussbericht); 2007 [cited 2007 28.06.2007]. Available from: http://www.biotechnologie.de/bio/generator/Redaktion/PDF/de/Studien/capgemini-regmed-2007,property=pdf.pdf.
39. Bombardier C., and Maetzel A. Pharmaeconomic evaluation of new treatments: efficacy versus effectiveness studies?. Annals of Rheumatic Diseases 58 Suppl I (1999) I82-I85
40. Goodman C.S. Healthcare technology assessment: methods, framework, and role in policy making. The American Journal of Managed Care 4 Special Issue (1998) SP200-SP214
41. Mauskopf J.A., Sullivan S.D., Annemans L., Caro J., Mullins C.D., Nuijten M., et al. Principles of good practice for budget impact analysis. Report of the ISPOR Task Force on Good Research Practices - Budget Impact Analysis. Value in Health 10 5 (2007) 336-347
42. Mauskopf J.A., Earnshaw S., and Mullins D.C. Budget impact analysis: review of the state of the art. Expert Review of Pharmacoeconomics & Outcomes Research 5 1 (2005) 65-79
43. Trueman P., Drummond M.F., and Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 19 6 (2001) 609-621